1. Home
  2. UVE vs GERN Comparison

UVE vs GERN Comparison

Compare UVE & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UNIVERSAL INSURANCE HOLDINGS INC

UVE

UNIVERSAL INSURANCE HOLDINGS INC

HOLD

Current Price

$38.95

Market Cap

957.6M

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.27

Market Cap

821.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVE
GERN
Founded
1990
1990
Country
United States
United States
Employees
N/A
258
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
957.6M
821.1M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
UVE
GERN
Price
$38.95
$1.27
Analyst Decision
Buy
Hold
Analyst Count
1
3
Target Price
$40.00
$2.17
AVG Volume (30 Days)
201.2K
14.2M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
1.97%
N/A
EPS Growth
214.43
N/A
EPS
1.88
N/A
Revenue
$1,603,915,000.00
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
$2.88
$43.75
P/E Ratio
$21.09
N/A
Revenue Growth
5.48
N/A
52 Week Low
$21.96
$1.04
52 Week High
$41.96
$2.01

Technical Indicators

Market Signals
Indicator
UVE
GERN
Relative Strength Index (RSI) 54.35 32.94
Support Level $38.29 $1.24
Resistance Level $41.58 $1.29
Average True Range (ATR) 1.18 0.09
MACD -0.21 -0.02
Stochastic Oscillator 27.15 10.42

Price Performance

Historical Comparison
UVE
GERN

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: